Expectations For This Clinical Trial Were to Slow Down ALS Progression; Instead it Reversed One Man’s Symptoms

  According to a recent article published in News NWA, in 2017 Mark Bedwell, of Fort Smith, Arkansas had been told that based upon the rapid progression of his amyotrophic…

Continue Reading Expectations For This Clinical Trial Were to Slow Down ALS Progression; Instead it Reversed One Man’s Symptoms
The Drug Fasenra has Earned Orphan Drug Designation to Treat Eosinophilic Esophagitis
Pexels / Pixabay

The Drug Fasenra has Earned Orphan Drug Designation to Treat Eosinophilic Esophagitis

According to a story from Check Orphan, the biopharmaceutical company AstraZeneca recently announced that its drug benralizumab (marketed as Fasenra) has earned Orphan Drug designation from the US Food and…

Continue Reading The Drug Fasenra has Earned Orphan Drug Designation to Treat Eosinophilic Esophagitis

After Being Part of a Crucial Spinal Muscular Atrophy Trial, a Family’s Future Remains Uncertain

According to a story from Palo Alto Online, it was only a few months into the life of Aleksandr Kostanyan when parents Svetlana Sargsyan and Tigran Kostanyan realized that something…

Continue Reading After Being Part of a Crucial Spinal Muscular Atrophy Trial, a Family’s Future Remains Uncertain
Abivax Begins Enrollment in Phase 2b Study of Experimental Ulcerative Colitis Treatment
jarmoluk / Pixabay

Abivax Begins Enrollment in Phase 2b Study of Experimental Ulcerative Colitis Treatment

According to a press release from French biotechnology company Abivax, the Company has successfully begun recruitment for its phase 2b clinical study of ABX464, its experimental once-a-day ulcerative colitis medication.…

Continue Reading Abivax Begins Enrollment in Phase 2b Study of Experimental Ulcerative Colitis Treatment
ICYMI: With the FDA’s Third Approval for Tissue Agnostic Therapies, Oncologists are Headed to the Next Level in Cancer Treatment
source: pixabay.com

ICYMI: With the FDA’s Third Approval for Tissue Agnostic Therapies, Oncologists are Headed to the Next Level in Cancer Treatment

Since the 1940s oncologists have been focusing on tumors at the location in the body where the tumors originated. According to a recent FDA press release, this is the third…

Continue Reading ICYMI: With the FDA’s Third Approval for Tissue Agnostic Therapies, Oncologists are Headed to the Next Level in Cancer Treatment
Experimental Treatment for Immune Thrombocytopenia Begins Trials in China
kalhh / Pixabay

Experimental Treatment for Immune Thrombocytopenia Begins Trials in China

According to a story from uk.finance.yahoo.com, the company Hutchison China MediTech Limited ("Chi-Med") has recently kicked off a phase 1 clinical trial. This trial is testing the company's investigational drug…

Continue Reading Experimental Treatment for Immune Thrombocytopenia Begins Trials in China
Rapid Whole Genome Sequencing is Getting Patients With Rare Genetic Disorders Diagnosed More Quickly
xresch / Pixabay

Rapid Whole Genome Sequencing is Getting Patients With Rare Genetic Disorders Diagnosed More Quickly

According to a story from the National Center for Advancing Translational Sciences (NCATS), research supported by the center is making it possible for kids born with serious, rare genetic disorders…

Continue Reading Rapid Whole Genome Sequencing is Getting Patients With Rare Genetic Disorders Diagnosed More Quickly
Proof of Concept Study of Investigative Primary Sclerosing Cholangitis Drug Begins
source: pixabay.com

Proof of Concept Study of Investigative Primary Sclerosing Cholangitis Drug Begins

According to a press release from the German-American biotechnology company Immunic Therapeutics, the Company recently began a proof-of-concept trial for its investigational primary sclerosing cholangitis treatment, IMU-838. About Primary Sclerosing…

Continue Reading Proof of Concept Study of Investigative Primary Sclerosing Cholangitis Drug Begins

Watch: Netflix Docuseries ‘Diagnosis’ About the Struggle of Diagnosing Mysterious Diseases 

Netflix debuted a documentary series this month called 'Diagnosis' -- based on a New York Times Magazine column -- which follows individuals with or caregiving for patients with a mysterious,…

Continue Reading Watch: Netflix Docuseries ‘Diagnosis’ About the Struggle of Diagnosing Mysterious Diseases 
FDA Grants Breakthrough Therapy Designation to Investigational Hepatitis D Treatment
Source: Pixabay.com

FDA Grants Breakthrough Therapy Designation to Investigational Hepatitis D Treatment

According to a press release from Eiger Biopharmaceuticals, the American Food and Drug Administration (FDA) recently granted the Company's experimental hepatitis delta virus drug (hepatitis D), peginterferon lambda, breakthrough therapy…

Continue Reading FDA Grants Breakthrough Therapy Designation to Investigational Hepatitis D Treatment
Study Finds That Denosumab can Boost Bone Density in Primary Biliary Cholangitis and Autoimmune Hepatitis
Free-Photos / Pixabay

Study Finds That Denosumab can Boost Bone Density in Primary Biliary Cholangitis and Autoimmune Hepatitis

According to a story from Healio, a recent study has illustrated that the drug denosumab can improve the bone density of patients with primary biliary cholangitis (PBC) and autoimmune hepatitis…

Continue Reading Study Finds That Denosumab can Boost Bone Density in Primary Biliary Cholangitis and Autoimmune Hepatitis
Synlogic Halts Development of Investigational Hyperammonemia Treatment SYNB1020
Bru-nO / Pixabay

Synlogic Halts Development of Investigational Hyperammonemia Treatment SYNB1020

According to a press release from Synlogic Therapeutics, the Company recently halted development of its investigational hyperammonemia treatment SYNB1020 after an unsuccessful phase 1/2 clinical study. About Hyperammonemia Hyperammonemia is…

Continue Reading Synlogic Halts Development of Investigational Hyperammonemia Treatment SYNB1020